Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or DMT.
Moreau told Proactive the safety review committee has approved moving the study forward with an escalated dose after observing no safety or tolerability issues. This study will include up to 60 healthy volunteers, including both psychedelic experienced and psychedelic naïve subjects.
Proactive Canada
+1 604-688-8158
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.12 |
Daily Change: | -0.0031 -2.60 |
Daily Volume: | 4,772 |
Market Cap: | US$2.540M |
April 01, 2024 January 11, 2024 November 30, 2023 |
UGE International develops, owns, and operates commercial and community solar projects in the United States and strategic markets abroad. Our distributed energy solutions deliver cheaper, cleaner energy to businesses and consumers...
CLICK TO LEARN MORESurf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS